The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

about

Immunotherapy for gastric cancers: emerging role and future perspectives.Advanced gastric adenocarcinoma: optimizing therapy options.Novel Targeted Therapies for Esophagogastric Cancer.Hypermutation and microsatellite instability in gastrointestinal cancers.

P2860

Q38738652-47CF04E3-7F03-43D3-8E9A-9E87B1D6E849 Q39091817-907FDD6B-3D62-4CBE-B29A-F6204C6B1A59 Q39171565-195E12B0-D4A5-4EDC-8495-2266E708AB11 Q47655313-0244B74D-0557-4A40-831C-D791983E06FE

P2860

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q38831655

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

@en

type

Item

label

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

@en

prefLabel

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

@en

P1476

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

@en

P2093

Bruno Bockorny

http://www.w3.org/2001/XMLSchema#string

Eirini Pectasides

http://www.w3.org/2001/XMLSchema#string

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Molecular and cellular insights into T cell exhaustion

Gene methylation in gastric cancer

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

P304

1833-1846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2217/FON-2016-0103

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27166503

http://www.w3.org/2001/XMLSchema#string

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

about

P2860

P2860

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698